top of page

BackTable / Urology / Contributor

Dr. Eugene Pietzak on the BackTable Urology Podcast

Dr. Eugene Pietzak

Urologic Oncologist

Dr. Eugene Pietzak is a urologic oncologist with Memoral Sloan Kettering in New York City.

Listen to Dr. Eugene Pietzak on the BackTable Urology Podcast

The BackTable Podcast is a knowledge resource by physicians for physicians. Learn from the experiences and expertise of Dr. Eugene Pietzak and get practical advice on how to build your practice by listening to the BackTable Urology Podcast.

Ep 64 Management of BCG-refractory NMIBC with Dr. Timothy Clinton and Dr. Eugene Pietzak
00:00 / 01:04

Stay Up To Date

Follow:

Subscribe:

Sign Up:

About Dr. Eugene Pietzak

Dr. Eugene Pietzak, MD, is a board-certified urologic surgeon who specializes in the surgical treatment of bladder cancer, prostate cancer, upper urothelial cancer, and other cancers of the genitourinary system. He has expertise in a wide array of surgical techniques, including minimally invasive and robotic surgery.

Dr. Pietzak received his medical degree from the State University of New York/Health Science Center at Stony Brook in 2010. He has over 14 years of experience, and is affiliated with St. Francis Hospital & Heart Center, Boca Raton Regional Hospital, New York Presbyterian Hospital, Stony Brook University Hospital, Guthrie Corning Hospital and Memorial Sloan Kettering Cancer Center.

Learn more by visiting Dr. Eugene Pietzak's practice:

Podcasts Featuring Dr. Eugene Pietzak

Episode #64

Urology

In this episode of BackTable Urology, Dr. Aditya Bagrodia speaks with two fellow urologic oncologists, Dr. Timothy Clinton (Brigham and Women’s Hospital) and Dr. Eugene Pietzak (Memorial Sloan Kettering), about the management of BCG-refractory non muscle-invasive bladder cancer.

Articles Featuring Dr. Eugene Pietzak

Histology of high grade bladder cancer

The management of high-grade BCG-unresponsive bladder cancer begins with the establishment of cytology and, based on the patient profile, is followed by either TURBT or total cystectomy. Alternatives to BCG for bladder cancer are available, but ongoing research continues to explore other options.

Cystoscopic Image of Bladder cancer

BCG-unresponsive bladder cancer has distinct criteria for diagnosis and management. Official FDA diagnosis requires the development or recurrence of a high-grade bladder tumor after a patient has received adequate BCG therapy. Treatment duration varies based on whether an induction or maintenance course is indicated.

Get Connected

Thank you for listening! If you have a question for Dr. Eugene Pietzak about a topic discussed on the BackTable Urology Podcast, you can get in touch with this form. Please note that our contributors are not able to respond to every inquiry.

Select which show(s) you would like to subscribe to:

Thanks! Message sent.

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

backtable-plus-vi-cta.jpg

Podcasts

Management of BCG-refractory NMIBC with Dr. Timothy Clinton and Dr. Eugene Pietzak on the BackTable Urology Podcast)
Perfecting Rectal Spacer Placement for Optimal Care with Dr. Neil Taunk on the BackTable Urology Podcast)

Topics

Bladder Cancer Condition Overview
Cystoscopy Procedure Prep

More Contributors

Dr. Neeraj Agarwal on the BackTable Urology Podcast

Dr. Neeraj Agarwal

Dr. Andrea Apolo on the BackTable Urology Podcast

Dr. Andrea Apolo

Dr. Aditya Bagrodia on the BackTable Urology Podcast

Dr. Aditya Bagrodia

Rick Bangs on the BackTable Urology Podcast

Rick Bangs

Dr. Sam Chang on the BackTable Urology Podcast

Dr. Sam Chang

Dr. Timothy Clinton on the BackTable Urology Podcast

Dr. Timothy Clinton

bottom of page